Ionis Pharmaceuticals Will Present New Three-year Data From The Phase 2 Open-label Extension Study As Well As Additional Results From The Pivotal Phase 3 OASIS and OASISplus Studies Of Donidalorsen For Hereditary Angioedema At The 2024 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals is set to present new three-year data from its Phase 2 open-label extension study and additional results from the Phase 3 OASIS and OASISplus studies of Donidalorsen for Hereditary Angioedema at the 2024 ACAAI Annual Scientific Meeting.
October 03, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals will present significant new data on Donidalorsen, a treatment for Hereditary Angioedema, at a major scientific meeting. This could impact investor sentiment positively.
The presentation of new data from both Phase 2 and Phase 3 studies at a major scientific meeting suggests potential advancements in Ionis's product pipeline, likely boosting investor confidence and stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90